Adhera Therapeutics, Inc. (ATRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | - USD | -98.53% |
| 2021 | - USD | 59.09% |
| 2020 | -1.99 Million USD | 80.31% |
| 2019 | -11.23 Million USD | 8.82% |
| 2018 | -16.27 Million USD | -96.75% |
| 2017 | -5.63 Million USD | -695.96% |
| 2016 | -708.54 Thousand USD | 82.24% |
| 2015 | -3.98 Million USD | -13.32% |
| 2014 | -5.47 Million USD | -864.38% |
| 2013 | -1.36 Million USD | 94.04% |
| 2012 | -7.23 Million USD | 62.48% |
| 2011 | -27.03 Million USD | 35.34% |
| 2010 | -23.36 Million USD | -138.23% |
| 2009 | -7.86 Million USD | 72.35% |
| 2008 | -46.57 Million USD | 23.58% |
| 2007 | -50.13 Million USD | -89.82% |
| 2006 | -26.41 Million USD | 17.38% |
| 2005 | -31.96 Million USD | -18.19% |
| 2004 | -26.7 Million USD | -199.44% |
| 2003 | -4.79 Million USD | 17.82% |
| 2002 | -11.58 Million USD | -26.23% |
| 2001 | -8.7 Million USD | 9.32% |
| 2000 | -9.6 Million USD | -5.53% |
| 1999 | -9.05 Million USD | -160.0% |
| 1998 | -2.05 Million USD | 50.7% |
| 1997 | -5.7 Million USD | 0.0% |
| 1996 | - USD | 100.0% |
| 1995 | -100 Thousand USD | -200.0% |
| 1994 | 100 Thousand USD | 143.48% |
| 1993 | -230 Thousand USD | 52.08% |
| 1992 | -480 Thousand USD | 15.79% |
| 1991 | -570 Thousand USD | -39.02% |
| 1990 | -410 Thousand USD | 24.07% |
| 1989 | -540 Thousand USD | 50.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -347 Thousand USD | 3.88% |
| 2023 Q3 | -269.49 Thousand USD | 64.45% |
| 2023 Q2 | -758 Thousand USD | -118.44% |
| 2022 Q4 | -361 Thousand USD | 34.12% |
| 2022 Q1 | -255 Thousand USD | -52.69% |
| 2022 Q2 | -449 Thousand USD | -76.08% |
| 2022 Q3 | -548 Thousand USD | -22.05% |
| 2022 FY | - USD | -98.53% |
| 2021 Q1 | -110 Thousand USD | 32.93% |
| 2021 Q3 | -409 Thousand USD | -217.05% |
| 2021 Q2 | -129 Thousand USD | -17.27% |
| 2021 FY | - USD | 59.09% |
| 2021 Q4 | -167 Thousand USD | 59.17% |
| 2020 Q1 | -1.32 Million USD | 49.5% |
| 2020 FY | - USD | 80.31% |
| 2020 Q2 | -316 Thousand USD | 76.11% |
| 2020 Q3 | -189 Thousand USD | 40.19% |
| 2020 Q4 | -164 Thousand USD | 13.23% |
| 2019 Q1 | -2.53 Million USD | 0.09% |
| 2019 Q3 | -2.2 Million USD | 20.24% |
| 2019 FY | - USD | 8.82% |
| 2019 Q4 | -2.62 Million USD | -19.04% |
| 2019 Q2 | -2.75 Million USD | -8.74% |
| 2018 Q2 | -4.51 Million USD | -313.41% |
| 2018 Q4 | -2.53 Million USD | 13.71% |
| 2018 Q3 | -2.94 Million USD | 34.87% |
| 2018 Q1 | -1.09 Million USD | 60.87% |
| 2018 FY | - USD | -96.75% |
| 2017 Q2 | -842.68 Thousand USD | 3.01% |
| 2017 FY | - USD | -695.96% |
| 2017 Q4 | -2.79 Million USD | -205.99% |
| 2017 Q1 | -868.87 Thousand USD | -175.87% |
| 2017 Q3 | -912.95 Thousand USD | -8.34% |
| 2016 Q1 | -3.06 Million USD | -395.0% |
| 2016 Q4 | 1.14 Million USD | 311.7% |
| 2016 Q3 | -541 Thousand USD | -584.81% |
| 2016 FY | - USD | 82.24% |
| 2016 Q2 | -79 Thousand USD | 97.43% |
| 2015 Q2 | -1.02 Million USD | 22.28% |
| 2015 FY | - USD | -13.32% |
| 2015 Q3 | -1.03 Million USD | -0.98% |
| 2015 Q1 | -1.31 Million USD | -93.67% |
| 2015 Q4 | -620 Thousand USD | 39.92% |
| 2014 FY | - USD | -864.38% |
| 2014 Q4 | -679 Thousand USD | 57.75% |
| 2014 Q3 | -1.6 Million USD | 69.47% |
| 2014 Q2 | -5.26 Million USD | -834.81% |
| 2014 Q1 | -563 Thousand USD | -2547.83% |
| 2013 Q2 | -186 Thousand USD | 42.94% |
| 2013 FY | - USD | 94.04% |
| 2013 Q4 | 23 Thousand USD | -81.45% |
| 2013 Q3 | 124 Thousand USD | 166.67% |
| 2013 Q1 | -326 Thousand USD | 81.5% |
| 2012 Q1 | -4.15 Million USD | -74.89% |
| 2012 FY | - USD | 62.48% |
| 2012 Q4 | -1.76 Million USD | -1972.94% |
| 2012 Q3 | -85 Thousand USD | 97.44% |
| 2012 Q2 | -3.31 Million USD | 20.09% |
| 2011 FY | - USD | 35.34% |
| 2011 Q1 | -6.05 Million USD | -42.43% |
| 2011 Q2 | -5.04 Million USD | 16.59% |
| 2011 Q3 | -4.22 Million USD | 16.4% |
| 2011 Q4 | -2.37 Million USD | 43.74% |
| 2010 Q4 | -4.24 Million USD | 57.3% |
| 2010 Q3 | -9.95 Million USD | -80.89% |
| 2010 Q2 | -5.5 Million USD | -69.89% |
| 2010 FY | - USD | -138.23% |
| 2010 Q1 | -3.23 Million USD | 65.04% |
| 2009 Q4 | -9.26 Million USD | -57.03% |
| 2009 Q1 | 9.15 Million USD | 182.23% |
| 2009 Q3 | -5.89 Million USD | -28.55% |
| 2009 Q2 | -4.58 Million USD | -150.11% |
| 2009 FY | - USD | 72.35% |
| 2008 Q3 | -2.6 Million USD | 80.0% |
| 2008 Q1 | -11.56 Million USD | -3.59% |
| 2008 FY | - USD | 23.58% |
| 2008 Q2 | -13.01 Million USD | -12.54% |
| 2008 Q4 | -11.13 Million USD | -327.98% |
| 2007 Q4 | -11.16 Million USD | 29.44% |
| 2007 Q3 | -15.82 Million USD | -32.52% |
| 2007 FY | - USD | -89.82% |
| 2007 Q2 | -11.93 Million USD | -6.41% |
| 2007 Q1 | -11.21 Million USD | -10.51% |
| 2006 FY | - USD | 17.38% |
| 2006 Q4 | -10.15 Million USD | -32.67% |
| 2006 Q1 | -8.09 Million USD | 9.47% |
| 2006 Q2 | -526 Thousand USD | 93.5% |
| 2006 Q3 | -7.65 Million USD | -1354.75% |
| 2005 FY | - USD | -18.19% |
| 2005 Q3 | -8.78 Million USD | -6.33% |
| 2005 Q4 | -8.94 Million USD | -1.85% |
| 2005 Q2 | -8.25 Million USD | -37.85% |
| 2005 Q1 | -5.99 Million USD | -7.71% |
| 2004 FY | - USD | -199.44% |
| 2004 Q4 | -5.56 Million USD | 22.44% |
| 2004 Q3 | -7.17 Million USD | -2.52% |
| 2004 Q2 | -6.99 Million USD | 4.49% |
| 2004 Q1 | -7.32 Million USD | -28.5% |
| 2003 Q4 | -5.69 Million USD | 4.67% |
| 2003 FY | - USD | 17.82% |
| 2003 Q1 | -2.35 Million USD | 48.43% |
| 2003 Q3 | -5.97 Million USD | -219.49% |
| 2003 Q2 | 8.8 Million USD | 312.08% |
| 2002 Q1 | -2.68 Million USD | 6.77% |
| 2002 Q2 | -1.21 Million USD | 54.65% |
| 2002 Q3 | -3.11 Million USD | -155.34% |
| 2002 Q4 | -4.57 Million USD | -47.07% |
| 2002 FY | - USD | -26.23% |
| 2001 FY | - USD | 9.32% |
| 2001 Q2 | -1.95 Million USD | 3.17% |
| 2001 Q4 | -2.88 Million USD | -71.49% |
| 2001 Q3 | -1.68 Million USD | 13.93% |
| 2001 Q1 | -2.19 Million USD | 42.69% |
| 2000 FY | - USD | -5.53% |
| 2000 Q2 | -2.23 Million USD | -1.64% |
| 2000 Q1 | -2.19 Million USD | 43.64% |
| 2000 Q3 | -1.65 Million USD | 128.96% |
| 2000 Q4 | -3.51 Million USD | -643.74% |
| 1999 Q4 | -3.9 Million USD | -143.75% |
| 1999 Q1 | -2.3 Million USD | -44.44% |
| 1999 Q2 | -1.6 Million USD | 38.46% |
| 1999 Q3 | -1.86 Million USD | 0.0% |
| 1999 FY | - USD | -160.0% |
| 1998 Q3 | -200 Thousand USD | -80.0% |
| 1998 Q2 | -500 Thousand USD | 0.0% |
| 1998 Q1 | -100 Thousand USD | 80.77% |
| 1998 Q4 | -1.5 Million USD | -100.0% |
| 1998 FY | - USD | 50.7% |
| 1997 Q3 | -1.6 Million USD | -17.65% |
| 1997 FY | - USD | 0.0% |
| 1997 Q4 | -2.3 Million USD | -30.0% |
| 1997 Q2 | -1.7 Million USD | -70.0% |
| 1997 Q1 | -1 Million USD | 0.0% |
| 1996 Q2 | 200 Thousand USD | 100.0% |
| 1996 Q1 | 100 Thousand USD | 125.0% |
| 1996 Q3 | -100 Thousand USD | -150.0% |
| 1996 FY | - USD | 100.0% |
| 1995 Q2 | -200 Thousand USD | 0.0% |
| 1995 Q1 | - USD | 100.0% |
| 1995 Q3 | -100 Thousand USD | 50.0% |
| 1995 Q4 | -400 Thousand USD | -300.0% |
| 1995 FY | - USD | -200.0% |
| 1994 Q2 | 100 Thousand USD | 200.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 FY | - USD | 143.48% |
| 1994 Q4 | -100 Thousand USD | -200.0% |
| 1994 Q1 | -100 Thousand USD | -200.0% |
| 1993 Q3 | 100 Thousand USD | 350.0% |
| 1993 FY | - USD | 52.08% |
| 1993 Q4 | 100 Thousand USD | 0.0% |
| 1993 Q2 | -40 Thousand USD | 0.0% |
| 1992 FY | - USD | 15.79% |
| 1991 FY | - USD | -39.02% |
| 1990 FY | - USD | 24.07% |
| 1989 FY | - USD | 50.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 100.0% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.0% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.0% |
| Mesoblast Limited | -62.38 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Genus plc | 73.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 100.0% |
| Marizyme, Inc. | -34.28 Million USD | 100.0% |
| ContraFect Corporation | -64.99 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.0% |
| EV Biologics, Inc. | -1.26 Million USD | 100.0% |
| Q BioMed Inc. | -617.62 Thousand USD | 100.0% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 100.0% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 100.0% |
| Biomind Labs Inc. | -1.03 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Pharming Group N.V. | 9.87 Million USD | 100.0% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 100.0% |
| Skye Bioscience, Inc. | -13.54 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 100.0% |
| IMV Inc. | -35.52 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 100.0% |
| GB Sciences, Inc. | -1.41 Million USD | 100.0% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| HST Global, Inc. | -5303.00 USD | 100.0% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.12 Million USD | 100.0% |
| Resverlogix Corp. | -11.74 Million USD | 100.0% |
| Affymax, Inc. | -14.29 Million USD | 100.0% |
| SYBLEU INC | -141.57 Thousand USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 100.0% |
| argenx SE | -216.02 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 100.0% |
| AVAX Technologies, Inc. | -6.11 Million USD | 100.0% |
| Zenith Capital Corp. | -8.6 Million USD | 100.0% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Helix BioMedix, Inc. | -1.04 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 100.0% |
| BioStem Technologies, Inc. | -7.55 Million USD | 100.0% |
| ONE Bio Corp. | 13.61 Million USD | 100.0% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 100.0% |
| Burzynski Research Institute, Inc. | - USD | NaN% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| LadRx Corporation | 412.28 Thousand USD | 100.0% |
| Cell Source, Inc. | -4.27 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 1.46 Million USD | 100.0% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 100.0% |
| NovAccess Global Inc. | -1.03 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 100.0% |
| Itoco Inc. | -1.86 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| Kadimastem Ltd | -2.62 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 100.0% |
| CytoDyn Inc. | -18.02 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 100.0% |
| Mobile Lads Corp. | -2.24 Million USD | 100.0% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 100.0% |
| Qrons Inc. | -40.08 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | -951 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 100.0% |
| International Stem Cell Corporation | 202 Thousand USD | 100.0% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -2.46 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -35.86 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -45 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 100.0% |
| Neutra Corp. | -181.24 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| PureTech Health plc | -11.62 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 100.0% |
| IXICO plc | -707 Thousand USD | 100.0% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.0% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 100.0% |